Moleculin Biotech, Inc. secures Japanese IP boost as Annamycin enters pivotal Phase 3
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.
Pharma & Biotech
Pharma & Biotech
FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.
Medical Devices & Diagnostics
What Applied Medical Technology’s Explant Express FDA clearance reveals about breast implant explantation workflows
FDA clears Explant Express for ruptured breast implant removal. Explore what this means for surgical workflows, adoption risks, and explantation standardisation.
Pharma & Biotech
Why Pulmovant’s PHocus study design matters for regulatory confidence in pulmonary hypertension associated with interstitial lung disease
Pulmovant completes PHocus enrollment for mosliciguat in PH-ILD. Find out what this milestone really means ahead of 2026 clinical data.
Features & Analysis
How Arcutis Biotherapeutics’ control of ZORYVE promotion could influence real-world dermatology and pediatric use
Arcutis Biotherapeutics takes full control of ZORYVE promotion. See how this shift could affect real-world dermatology and pediatric prescribing.
Medical Devices & Diagnostics
BioStem acquires Neox and Clarix as BioTissue refocuses on eye care therapies
BioTissue exits surgical wound care to refocus on eye care innovation, selling Neox and Clarix lines to BioStem. Find out what this deal changes in MedTech.